Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Gynecologic Cancers
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
What are your top takeaways in Breast Cancer from ASCO 2024?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
How would you manage a patient who develops acute stroke during neoadjuvant chemotherapy with KEYNOTE-522 for Stage III triple negative breast cancer?
How do you approach a breast cancer patient with outside pathology returning as HER2 positive on FISH but internal pathology review showing conflicting results and HER2 negative on FISH on same sample?
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
Would you consider chemoimmunotherapy (CP-Pembro-AC) in triple negative breast cancer if tumor is not palpable on physical exam?
Would you offer adjuvant chemotherapy to a premenopausal woman with HR+ HER2 negative IDC, T1cN0, with isolated tumor cells, oncotype RS 20, grade 2, with multifocal LVI?
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
